Abstract:Estrogens have complex effects on the skeleton, including regulation of modeling and maintenance of bonemass, which vary with cell type and developmental stage. Osteoblasts are key regulators of skeletal matrix synthesis and degradation. However, whether osteocytes, osteoblasts or earlier progenitors mediate estrogen effects, and the importance of estrogen receptors (ERs) alpha and beta, remain unclear. To address estrogen response in human cells closely related to secretory osteoblasts, we studied MG63 cells with ERalpha or ERbeta reduced to low levels by stable transfection of antisense plasmids. Collagen and alkaline phosphatase expression increased with estrogen in wild-type and ERalpha-suppressed cells, but not in ERbeta-suppressed cells. Matrix secretion occurs as osteoblasts cease dividing, and, in keeping with this, cell proliferation was reduced by estrogen except in ERbeta-antisense cells. No effects of estrogen on wild type or ER-suppressed cells were seen in expression of BMP 2, the BMP antagonist noggin, or Indian hedgehog, products that regulate differentiation of osteoblasts. In contrast to expectations that estrogen would modulate bone degradation, RANKL, CSF-1, and osteoprotegerin did not respond measurably to estrogen, regardless of ER status. In keeping with this result, estrogen response was not observed in assays of osteoclast development from CD14 cells supported by wild-type or ER-silenced MG63 cells. Since estrogens are major regulators of bone degradation in vivo, estrogen effects on osteoclasts may depend on interaction with stimuli present in bone but absent in the model studied. cDNA hybridization showed that additional estrogen-binding proteins including ERRalpha and BCAR3 were expressed by MG63, but estrogen effects in ERbeta-silenced cells were small, so these proteins are either minor regulators in MG63 cells, or act in concert with stimuli in addition to estrogen. We conclude that, in the MG63 cell line, estrogen increases synthesis of matrix proteins via ERbeta, and that, in the absence of additional stimuli, these cells are not major mediators of estrogen effects on osteoclast differentiation. Further, ERalpha is probably much more important in earlier stages of skeletal development, such as growth plate response, than in osteoblasts. (C) 2003 Wiley-Liss, Inc.

Estrogen Stimulates Osteoprotegerin Expression Via the Suppression of Mir-145 Expression in MG-63 Cells

Erxian decoction potentially prevents postmenopausal osteoporosis by modulating miR-335: a study based on bioinformatics analysis and preliminary clinical case validation

Estrogen inhibits osteoclasts formation and bone resorption via microRNA‐27a targeting PPARγ and APC

microRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation

Estrogen promotes lncRNA H19 expression to regulate osteogenic differentiation of BMSCs and reduce osteoporosis via miR-532-3p/SIRT1 axis

Identification of the canonical and noncanonical role of miR-143/145 in estrogen-deficient bone loss

Overexpression of miR-195-5p reduces osteoporosis through activating BMP-2/SMAD/Akt/RUNX2 pathway via targeting SMURF1.

Estrogen receptor-beta modulates synthesis of bone matrix proteins in human osteoblast-like MG63 cells.

Mir-664-3p Suppresses Osteoblast Differentiation And Impairs Bone Formation Via Targeting Smad4 And Osterix

[Effect of Estrogen on Osteoprotegerin, Osteoclast Differentiation Factor and Macrophage Colony Stimulating Factor Mrna Expressions in Ovariectomized Rat Bone Tissue].

Silencing of miR-483-5p alleviates postmenopausal osteoporosis by targeting SATB2 and PI3K/AKT pathway

MicroRNA-764-3p regulates 17β-estradiol synthesis of mouse ovarian granulosa cells by targeting steroidogenic factor-1

Mir-381-3p aggravates ovariectomy-induced osteoporosis by inhibiting osteogenic differentiation through targeting KLF5/Wnt/β-catenin signaling pathway

Identification of Suitable Reference Gene and Biomarkers of Serum Mirnas for Osteoporosis

MiR-146a Deletion Protects From Bone Loss in OVX Mice by Suppressing RANKL/OPG and M-CSF in Bone Microenvironment

Circulating miR-338 Cluster activities on osteoblast differentiation: Potential Diagnostic and Therapeutic Targets for Postmenopausal Osteoporosis

Silencing Mir-106 B Accelerates Osteogenesis of Mesenchymal Stem Cells and Rescues Against Glucocorticoid-Induced Osteoporosis by Targeting BMP 2

Mir-Oz Kegulates Osteoblast Apoptosis, Proliferation and Differentiation Through Targeted Inhibition of Runx2 in Osteoporosis Running Title: Role and Potential Mechanism of Mir-152 in Osteoporosis

Estrogen regulates expression of osteoprotegerin and RANKL in human periodontal ligament cells through estrogen receptor beta.

Osteoclast-derived Exosomal Mir-214-3p Inhibits Osteoblastic Bone Formation.

MicroRNA-17-92a Upregulation by Estrogen Leads to Bim Targeting and Inhibition of Osteoblast Apoptosis